<div id="readability-page-1"><p>Pacer Advisors Inc. bought a new position in  Illumina, Inc. (NASDAQ:ILMN - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor  bought 649,290 shares of the life sciences company's stock, valued at approximately $61,663,000. Pacer Advisors Inc. owned approximately 0.42% of Illumina as of its most recent SEC filing.</p><ul><li>GRAIL: Biotech Stock Targeting $100B Cancer Market</li></ul><p>A number of other institutional investors also recently modified their holdings of the stock. Wellington Management Group LLP raised its holdings in shares of  Illumina by 47.1% during the first quarter. Wellington Management Group LLP now owns 37,213 shares of the life sciences company's stock worth $2,952,000 after acquiring an additional 11,915 shares in the last quarter.  Ieq Capital LLC increased its position in  Illumina by 141.3% in the 1st quarter. Ieq Capital LLC now owns 68,798 shares of the life sciences company's stock worth $5,458,000 after purchasing an additional 40,291 shares during the last quarter.  BNP Paribas Financial Markets increased its position in  Illumina by 49.9% in the 1st quarter. BNP Paribas Financial Markets now owns 884,896 shares of the life sciences company's stock worth $70,208,000 after purchasing an additional 294,609 shares during the last quarter.  Landscape Capital Management L.L.C. acquired a new stake in shares of  Illumina during the 1st quarter valued at about $376,000.  Finally, Trexquant Investment LP grew its stake in shares of  Illumina by 52.7% in the 1st quarter. Trexquant Investment LP now owns 218,369 shares of the life sciences company's stock valued at $17,325,000 after buying an additional 75,392 shares in the last quarter. Institutional investors and hedge funds own  89.42% of the company's stock. </p><h2>Illumina Stock Performance</h2><p>Shares of NASDAQ ILMN opened at $134.95 on Friday. The company has a quick ratio of 1.12, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The business's 50 day moving average is $122.45 and its two-hundred day moving average is $106.18. The company has a market cap of $20.62 billion, a P/E ratio of 30.26, a P/E/G ratio of 2.42 and a beta of 1.44. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $153.06. </p><ul><li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li></ul><p>Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The company had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.07 billion. During the same period in the prior year, the business earned $1.14 earnings per share. Illumina's revenue for the quarter was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS.  On average, equities analysts expect that  Illumina, Inc. will post 4.51 EPS for the current year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>ILMN has been the topic of several recent research reports. UBS Group raised their price objective on shares of Illumina from $110.00 to $120.00 and gave the company a &#34;neutral&#34; rating in a research report on Friday, October 31st. Cowen  restated a &#34;hold&#34; rating on shares of Illumina in a research note on Friday, October 31st. Canaccord Genuity Group lifted their price objective on shares of Illumina from $112.00 to $130.00 and gave the company a &#34;hold&#34; rating in a research note on Monday, December 22nd. JPMorgan Chase &amp; Co. increased their target price on shares of Illumina from $105.00 to $130.00 and gave the stock a &#34;neutral&#34; rating in a research report on Monday, December 15th. Finally, Weiss Ratings  reaffirmed a &#34;hold (c-)&#34; rating on shares of Illumina in a research report on Monday. One research analyst  has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Illumina currently has an average rating of &#34;Hold&#34; and a consensus price target of $118.31.</p><ul><li>Palantir Was Left Out of the S&amp;P 500; It Still Looks Like a Buy</li></ul><p><b>Get Our Latest Stock Report on Illumina</b></p><h2>Insider Buying and Selling at Illumina</h2><p>In related news, insider Scott M. Davies sold 323 shares of the business's stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Scott Gottlieb purchased 500 shares of the business's stock in a transaction on Monday, November 3rd. The stock was purchased at an average cost of $122.13 per share, with a total value of $61,065.00. Following the acquisition, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own  2.60% of the company's stock. </p><h2>Illumina Profile</h2> (Free Report)<p>Illumina, Inc <span>NASDAQ: ILMN<span></span></span> is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.  </p><p>The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Illumina</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Do you know what Amazon is planning for January 1?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><strong>Want to see what other hedge funds are holding ILMN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUxNTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUxNTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Illumina Right Now?</h2><p>Before you consider Illumina, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.</p><p>While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ILMN

<p>Pacer Advisors Inc. acquired 649,290 shares of Illumina, Inc., valued at approximately $61.66 million, in the third quarter, as per their SEC filing. This acquisition represents about 0.42% ownership in Illumina. The company's stock performance shows a market cap of $20.62 billion, with a recent quarterly earnings report exceeding expectations. Analysts have given Illumina a consensus "Hold" rating with a price target of $118.31.</p>

Pacer Advisors Inc. Acquires New Position in Illumina, Inc. $ILMN